ATE533486T1 - Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung - Google Patents

Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung

Info

Publication number
ATE533486T1
ATE533486T1 AT06791093T AT06791093T ATE533486T1 AT E533486 T1 ATE533486 T1 AT E533486T1 AT 06791093 T AT06791093 T AT 06791093T AT 06791093 T AT06791093 T AT 06791093T AT E533486 T1 ATE533486 T1 AT E533486T1
Authority
AT
Austria
Prior art keywords
pyridone derivatives
preventing
lung injury
radiotherapy
related lung
Prior art date
Application number
AT06791093T
Other languages
English (en)
Inventor
Tieling Zhou
Ying Luo
Jun Wu
Original Assignee
Shanghai Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Genomics Inc filed Critical Shanghai Genomics Inc
Application granted granted Critical
Publication of ATE533486T1 publication Critical patent/ATE533486T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT06791093T 2006-06-15 2006-09-25 Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung ATE533486T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80491406P 2006-06-15 2006-06-15
PCT/CN2006/002504 WO2007147297A1 (fr) 2006-06-15 2006-09-25 Utilisation de dérivés de pyridone destinés à prévenir et traiter par radioactivité une lésion des poumons

Publications (1)

Publication Number Publication Date
ATE533486T1 true ATE533486T1 (de) 2011-12-15

Family

ID=38833053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06791093T ATE533486T1 (de) 2006-06-15 2006-09-25 Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung

Country Status (7)

Country Link
US (2) US8765726B2 (de)
EP (1) EP2036555B1 (de)
JP (1) JP5213852B2 (de)
CN (1) CN101484167B (de)
AT (1) ATE533486T1 (de)
CA (1) CA2656017C (de)
WO (1) WO2007147297A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471534A1 (de) 2006-12-18 2012-07-04 Intermune, Inc. Verfahren zur Bereitstellung einer Pirfenidontherapie an einen Patienten
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2968292A4 (de) 2013-03-15 2016-11-23 Intermune Inc Verfahren zur verbesserung der mikrovaskulären integrität
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2016127013A1 (en) * 2015-02-05 2016-08-11 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
MX2021013944A (es) * 2019-05-13 2022-04-01 Bio Medical Sciences Inc Productos para el tratamiento de heridas y cicatrices con ingredientes activos, procedimiento de fabricacion y articulos utiles.
EP4326265A4 (de) * 2021-04-19 2024-12-25 Gyre Therapeutics, Inc. Pharmazeutische hydrnidonformulierungen für krankheiten
CN115429802A (zh) * 2021-06-04 2022-12-06 北京康蒂尼药业股份有限公司 包含羟尼酮与右美沙芬的药物组合物及其治疗肺纤维化的应用
CN113274389B (zh) * 2021-07-09 2022-11-08 中南大学 氟非尼酮在制备治疗急性肺损伤药物中的应用
WO2026077441A1 (en) * 2024-10-12 2026-04-16 Beijing Continent Pharmaceuticals Co., Ltd. Compositions and methods for preventing and treating chronic kidney disease
WO2026077440A1 (en) * 2024-10-12 2026-04-16 Beijing Continent Pharmaceuticals Co., Ltd. Compositions and methods for preventing and treating chronic renal failure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
AU5427080A (en) 1979-01-08 1980-07-17 Margolin, B. Pirfenidone in the treatment of pulmonary interstitial fibrosis
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
JPH08510251A (ja) 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6114353A (en) * 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
CA2388840C (en) * 2000-01-24 2011-09-13 Solomon B. Margolin Treatment of lymphomas, leukemias, breast carcinomas, astrocytomas, melanomas, leiomyomas, and related tumors
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
EP1551369A4 (de) * 2002-08-28 2007-05-09 Intermune Inc Kombinationstherapie zur behandlung von fibrotischen erkrankungen
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CN100358872C (zh) * 2003-11-14 2008-01-02 上海睿星基因技术有限公司 吡啶酮衍生物及其应用
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途

Also Published As

Publication number Publication date
EP2036555A4 (de) 2009-11-11
CA2656017C (en) 2014-02-04
CN101484167B (zh) 2012-07-04
US20140249347A1 (en) 2014-09-04
JP2009539887A (ja) 2009-11-19
US20080161361A1 (en) 2008-07-03
EP2036555A1 (de) 2009-03-18
JP5213852B2 (ja) 2013-06-19
US8765726B2 (en) 2014-07-01
WO2007147297A1 (fr) 2007-12-27
CN101484167A (zh) 2009-07-15
CA2656017A1 (en) 2007-12-27
EP2036555B1 (de) 2011-11-16

Similar Documents

Publication Publication Date Title
ATE533486T1 (de) Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
CY1110901T1 (el) Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
BRPI0607017A2 (pt) métodos e composições para o tratamento de condições relacionadas ao snc
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
ATE521608T1 (de) Glucokinaseaktivatoren
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PH12015502549A1 (en) Heterocyclic derivatives
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
SG195383A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602005008241D1 (de) Zusammensetzung mit einem survivin-antisense-oligonucleotid und gemcitabin zur behandlung von krebs
DE602005009162D1 (de) Alpha-aminoamidderivate zur behandlung des restless-leg-syndroms
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
WO2011140198A3 (en) Compounds and methods of treating brain disorders